Goldman Medical's semi-annual report exceeded expectations and launched equity incentives, and the recovery logic of ICL's leading company was confirmed (Goldman Sachs)
KingMed's net profit in the first half of 2026 exceeded Goldman Sachs' expectations, and it also launched a new equity incentive plan that has taken into account the impact of policies such as DRG 3.0.
KingMed's net profit in the first half of 2026 exceeded Goldman Sachs' expectations, and it also launched a new equity incentive plan that has taken into account the impact of policies such as DRG 3.0. As the leading independent clinical laboratory (ICL) in China, the company will benefit from the increased penetration of outsourcing and market integration in the industry. One-sentence conclusion: KingMed Medical has announced that it has entered the performance recovery channel with its better-than-expected performance and equity incentives. The risk-return ratio under the current valuation is very favorable. Positive/negative: Positive for KingMed Medical (603882) and the ICL industry. Performance exceeding expectations and incentive plans are powerful catalysts for stock prices, and the market has not yet fully responded to this. Catalysts: 1) The impact of the actual implementation of the DRG/DIP policy on ICL’s business volume; 2) The recovery of accounts receivable; 3) The expansion progress of the special inspection project.